cardiovascular outcomes
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
... Over a median follow-up period of 2.8 years, with more than 8000 patients who were eligible to be followed for 3 to 5 years and 6444 patients who received the assigned alirocumab or place- bo for at least 3 years, the ...
11
Cardiovascular outcomes associated with use of clarithromycin : population based study
... analysis we trimmed the first and 20th propensity score strata (see supplementary material 4). Along with other initial adjustment variables, we also used the estimated propensity score as an adjustment variable in the ...
12
Computing and interpreting the Number Needed to Treat for Cardiovascular Outcomes Trials
... of Cardiovascular Outcomes Trials (CVOTs) in type 2 diabetes have clearly established the cardio- vascular (CV) safety or even the benefit of two therapeutic classes, Glucagon-Like Peptide-1 receptor ...
10
Testosterone replacement therapy and the risk of adverse cardiovascular outcomes and mortality
... Our study found that in men with secondary hypo- gonadism unrelated to overt pituitary disease, with a modest prevalence of CVD, no difference in the risk of the composite outcome in men exposed to TRT vs. those that ...
8
<p>Prediction of cardiovascular outcomes with machine learning techniques: application to the Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) study</p>
... composite cardiovascular outcomes in ...adverse outcomes by the models, while eGFR, based on the CKD-epidemiology collaboration cystatin C equation, was selected by only one model as the fourth in ...
10
Cardiovascular Outcomes Following Rotational Atherectomy: A UK Multicentre Experience
... © 2016 Wiley Periodicals, Inc. This is the peer reviewed version of the following article: Eftychiou, C., Barmby, D. S., Wilson, S. J., Ubaid, S., Markwick, A. J., Makri, L., Blaxill, J. M., Spratt, J. C., Gunning, M. ...
18
The relationship between depression, anxiety, and cardiovascular outcomes in patients with acute coronary syndromes
... on cardiovascular outcomes among patients with myocardial ischemic events? There has been a relative paucity of stud- ies in this area and thus far the results have been ...adverse cardiovascular ...
14
<p>Relationship of inhaled long-acting bronchodilators with cardiovascular outcomes among patients with stable COPD: a meta-analysis and systematic review of 43 randomized trials</p>
... overall cardiovascular safety, the risk of speci- fi c cardiovascular outcomes such as arrhythmia, heart fail- ure and stroke is still ...and cardiovascular outcomes including overall ...
10
Association of diabetes-related kidney disease with cardiovascular and non-cardiovascular outcomes: a retrospective cohort study
... and outcomes, but we purchased the most data possible within the study budget (as well as the most recent data available at the time the study ...the outcomes we ...
11
Long-term Cardiovascular Outcomes in Survivors of Kawasaki Disease
... long-term outcomes of in- terest for this study were acute coronary syndrome, congestive heart failure, percutaneous coronary intervention, coronary artery bypass grafting, life- threatening ventricular arrhythmia ...
9
Impact of olmesartan on blood pressure, endothelial function, and cardiovascular outcomes
... BP reduction is the most effective way to reduce CV risk in patients with hypertension. Some antihypertensive agents have additional benefits that are independent of BP. Olmesartan effectively reduces BP and also has ...
11
<p>Validity of Claims Diagnosis Codes for Cardiovascular Diseases in Diabetes Patients in Japanese Administrative Database</p>
... of outcomes is important in such studies, validation studies from Japan are still scarce and small in scale with questions remaining on the representativeness of their fi ...of outcomes that often develop in ...
9
Comparing marginal structural models to standard methods for estimating treatment effects of antihypertensive combination therapy
... clinical outcomes, and suggest that aggressive management of hypertension may not only result in higher achievement rates of target blood pressure [12] but also in clinically important reduction in ...
8
Association_Between_Bilirubin_Atazanavir_and.5.pdf
... and cardiovascular outcomes in general, and whether there is a protective effect of mildly elevated bilirubin levels not due to liver disease and the role of specific antiretroviral medications, potentially ...
7
Alcohol and Immediate Risk of Cardiovascular Events: A Systematic Review and Dose-Response Meta-Analysis
... and cardiovascular outcomes are more likely to result from differences in lifestyle and the frequency and amount of alcohol intake rather than from different physiologic effects of a specific beverage ...
18
Soluble Klotho is associated with mortality and cardiovascular events in hemodialysis
... with cardiovascular events and mortality in the general population and various sub-populations ...affect cardiovascular outcomes, including age, dialysis vintage, comorbid conditions such as ...
10
Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes
... the cardiovascular system, and their potential involvement in major adverse cardio- vascular events ...improved cardiovascular outcomes remains uncertain and needs yet to be ...
13
Pharmacogenomics in Hypertension: Where We Stand Today
... 21. McDonough, C.W.; Burbage, S.E.; Duarte, J.D.; Gong, Y.; Langaee, T.Y.; Turner, S.T.; Gums, J.G.; Chapman, A.B.; Bailey, K.R.; Beitelshees, A.L., et al. Association of variants in NEDD4L with blood pressure response ...
33
Association of high-density lipoprotein cholesterol with non-fatal cardiac and non-cardiac events: a CANHEART substudy
... non-fatal outcomes, defined using the International Classification of Diseases, 10th revision, ascertained using the adminis- trative databases linked as part of the CANHEART ...Non-fatal outcomes that were ...
9
Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D)
... and Cardiovascular Outcomes in Participants with Diabetic Nephropathy; DECLARE-TIMI, Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events; ELIXA, ...
8